Medicure (TSE:MPH) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Medicure Inc. has signed an agreement to acquire intellectual property from CanAm Bioresearch Inc., focusing on new chemical entities with potential therapeutic applications. The deal includes an initial cash payment and additional milestone payments upon filing and approval of new drug applications. Medicure expects these acquisitions to enhance its pharmaceutical development and commercialization efforts in the United States.
For further insights into TSE:MPH stock, check out TipRanks’ Stock Analysis page.
